ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Nicholas Investment Partners LP

Nicholas Investment Partners LP trimmed its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 37.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 177,382 shares of the biotechnology company's stock after selling 106,314 shares during the period. Nicholas Investment Partners LP owned about 0.08% of ADMA Biologics worth $3,042,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Miura Global Management LLC grew its holdings in shares of ADMA Biologics by 25.0% in the 4th quarter. Miura Global Management LLC now owns 50,000 shares of the biotechnology company's stock worth $858,000 after acquiring an additional 10,000 shares during the period. Morse Asset Management Inc grew its holdings in shares of ADMA Biologics by 3,144.4% in the 4th quarter. Morse Asset Management Inc now owns 7,300 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 7,075 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ADMA Biologics by 7.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 148,638 shares of the biotechnology company's stock worth $2,556,000 after acquiring an additional 10,047 shares during the period. Lazard Asset Management LLC grew its holdings in shares of ADMA Biologics by 38.4% in the 4th quarter. Lazard Asset Management LLC now owns 348,599 shares of the biotechnology company's stock worth $5,977,000 after acquiring an additional 96,689 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in shares of ADMA Biologics by 16.3% in the 4th quarter. Janus Henderson Group PLC now owns 107,161 shares of the biotechnology company's stock worth $1,837,000 after acquiring an additional 15,000 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 0.3%

Shares of ADMA Biologics stock traded up $0.06 during trading hours on Monday, reaching $19.75. 676,964 shares of the company's stock were exchanged, compared to its average volume of 3,706,839. ADMA Biologics, Inc. has a 52-week low of $9.22 and a 52-week high of $25.67. The firm has a market capitalization of $4.71 billion, a price-to-earnings ratio of 70.48 and a beta of 0.57. The company has a fifty day moving average of $20.49 and a 200-day moving average of $18.86. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the business posted $0.08 earnings per share. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ADMA shares. Raymond James increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. StockNews.com cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.